46558results about "Anti-inflammatory agents" patented technology

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Provided herein are compounds having a Formula (I), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, and / or in treating various diseases such as cancer.

The invention relates to the field of medicinal chemistry, in particular to a substituted quinolinone compound targeting KRASG12D and application of the substituted quinolinone compound. Pharmacological tests prove that the affinity effect of the synthesized compound on a KRASG12D mutant is superior to that of a lead compound KAL-21404358. The compounds WY1-014 and WY1-062 have ideal inhibition effects on cells of human lung cancer (A549), human melanoma (A375) and human colon cancer (LOVO). The compound WY1-062 has excellent anti-tumor activity, and the activity of the compound WY1-062 is superior to that of cis-platinum.

New Treatments for Pain The Application describes new SOS1 inhibitors for use in the treatment of pain and cancer.

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

The invention relates to a phenyl-containing heterocyclic derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (XVI), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, each substituent in the general formula (XVI) being as defined in the specification # imgabs0 #

The invention discloses an oral solid preparation melogabalin besylate tablet containing an excellent stabilizer and a preparation method thereof. A tablet core contains but is not limited to melogabalin besylate, one or two or more filling agents, one or two or more disintegrating agents, one or two or more flow aids and various stabilizer compositions. According to the invention, the optimal stabilizer composition is selected through investigation, so that the growth of main degradation impurities and oxidation impurities is effectively controlled, the product stability is improved, and the tablets with stable quality are obtained. The product is rapidly dissolved out, the dissolution uniformity is good, the intermediate tabletting is smooth, the compressibility is good, and the prepared finished product is good in appearance, free of small holes and stable and controllable in quality.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The present application discloses compounds of formula I for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.

Described herein are sodium channels inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder, including pains.

The invention discloses red ginseng fermentation liquor with high rare saponin content and functional bioactivity and a preparation method thereof, and the preparation method comprises the following steps: mixing red ginseng powder with water to obtain red ginseng mixed liquor; cellulase is added into the red ginseng mixed solution for enzymolysis, and red ginseng enzymatic hydrolysate is obtained; or heating the red ginseng liquid, and performing hot water extraction to obtain a red ginseng extracting solution; heating the red ginseng extracting solution to be boiled, and after sterilization is finished, adding lactic acid bacteria powder for fermentation after the red ginseng solution is cooled, so as to obtain red ginseng fermentation liquor; and carrying out solid-liquid separation on the fermentation broth to obtain a fermentation supernatant, and sterilizing the red ginseng fermentation broth to obtain the sterilized red ginseng fermentation broth. According to the preparation method disclosed by the invention, the content of total saponins in the red ginseng fermentation liquor is increased, the variety and content of rare saponins can be increased, and in addition, the prepared red ginseng fermentation liquor has relatively high antioxidant activity, tyrosinase inhibition rate activity, leukoproteinase inhibition activity and hyaluronidase inhibition activity; wide application prospects and market potentials are realized.

The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.

Provided are diaminocyclopentyl substituted heteroaryl derivatives, the use thereof and a preparation method therefor. In particular, the present disclosure relates to compounds represented by formula (I)each substituent of which is defined in the description, and a preparation method therefor. The compounds can be used as PCSK9 inhibitors to prevent and / or treat PCSK9-mediated diseases and disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

The invention relates to the field of microorganisms, in particular to bifidobacterium adolescentis YG3912, inactivated thalli, an extract, a culture, a culture supernatant, a fermentation product and / or a fermentation supernatant of the bifidobacterium adolescentis YG3912, an application of the bifidobacterium adolescentis YG3912 in preparation of a composition for promoting skin repair, reducing skin inflammation or allergy, improving skin quality and improving skin quality. The invention also relates to application of the composition in products for resisting skin aging and enhancing skin immune function. The bifidobacterium adolescentis YG3912 and the related products thereof have the advantages that the bifidobacterium adolescentis YG3912 and the related products of the bifidobacterium adolescentis YG3912 are high in skin cell repairing capacity, skin inflammation relieving, inhibiting or eliminating capacity and remarkable in skin aging resisting capacity, so that the bifidobacterium adolescentis YG3912 and the related products of the bifidobacterium adolescentis YG3912 are expected to be used for skin health care such as skin repairing, inflammation relieving and light aging resisting, and the bifidobacterium adolescentis YG3912 and the related products thereof have remarkable application value and market potential.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.